Small Molecule IITR00693 (2-Aminoperimidine) Synergizes Polymyxin B Activity against Staphylococcus aureus and Pseudomonas aeruginosa.

The rise of antibiotic resistance among skin-infecting pathogens poses an urgent threat to public health and has fueled the search for new therapies. Enhancing the potency of currently used antibiotics is an alternative for the treatment of infections caused by drug-resistant pathogens. In this study, we aimed to identify a small molecule that can potentiate currently used antibiotics. IITR00693 (2-aminoperimidine), a novel antibacterial small molecule, potentiates the antibacterial activity of polymyxin B against Staphylococcus aureus and Pseudomonas aeruginosa. Herein, we investigated in detail the mode of action of this interaction and the molecule's capability to combat soft-tissue infections caused by S. aureus and P. aeruginosa. A microdilution checkerboard assay was performed to determine the synergistic interaction between polymyxin B and IITR00693 in clinical isolates of S. aureus and P. aeruginosa. Time-kill kinetics, post-antibiotic effect, and resistance generation studies were performed to assess the pharmacodynamics of the combination. Assays based on different fluorescent probes were performed to decipher the mechanism of action of this combination. The in vivo efficacy of the IITR00693-polymyxin B combination was determined in a murine acute wound infection model. IITR00693 exhibited broad-spectrum antibacterial activity. IITR00693 potentiated polymyxin B and colistin against polymyxin-resistant S. aureus. IITR00693 prevented the generation of resistant mutants against multiple antibiotics. The IITR00693-polymyxin B combination decreased the S. aureus count by >3 log10 CFU in a murine acute wound infection model. IITR00693 is a potential and promising candidate for the treatment of soft-tissue infections along with polymyxins.

[1]  J. Gumbart,et al.  Restoring and Enhancing the Potency of Existing Antibiotics against Drug-Resistant Gram-Negative Bacteria through the Development of Potent Small-Molecule Adjuvants. , 2022, ACS infectious diseases.

[2]  Jiangtao Xu,et al.  Two plus One: Combination Therapy Tri-systems Involving Two Membrane-Disrupting Antimicrobial Macromolecules and Antibiotics. , 2022, ACS infectious diseases.

[3]  J. Haldar,et al.  Small-Molecular Adjuvants with Weak Membrane Perturbation Potentiate Antibiotics against Gram-Negative Superbugs. , 2022, ACS infectious diseases.

[4]  M. H. Wong,et al.  Active maintenance of proton motive force mediates starvation-induced bacterial antibiotic tolerance in Escherichia coli , 2021, Communications Biology.

[5]  R. Pathania,et al.  Mechanistic insights into synergy between nalidixic acid and tetracycline against clinical isolates of Acinetobacter baumannii and Escherichia coli , 2021, Communications biology.

[6]  F. Franceschi,et al.  Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. , 2021, International journal of antimicrobial agents.

[7]  S. Ding,et al.  A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens , 2020, Nature Microbiology.

[8]  A. Kothari,et al.  Assessment of polymyxin B - doxycycline combination against Pseudomonas aeruginosa in in vitro and in a mouse acute pneumonia model. , 2020, International journal of antimicrobial agents.

[9]  R. Gennis,et al.  Role of respiratory NADH oxidation in the regulation of Staphylococcus aureus virulence , 2020, EMBO reports.

[10]  Zhiliang Yu,et al.  Mechanisms of bactericidal action and resistance of polymyxins for Gram-positive bacteria , 2020, Applied Microbiology and Biotechnology.

[11]  Ana Rita Brochado,et al.  Proton Motive Force Disruptors Block Bacterial Competence and Horizontal Gene Transfer. , 2020, Cell host & microbe.

[12]  Emma J. Chory,et al.  A Deep Learning Approach to Antibiotic Discovery , 2020, Cell.

[13]  Daniel J. Shapiro,et al.  National Trends in Incidence of Purulent Skin and Soft Tissue Infections in Patients Presenting to Ambulatory and Emergency Department Settings, 2000-2015. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Pathania,et al.  Antibacterial properties and in vivo efficacy of a novel nitrofuran, IITR06144, against MDR pathogens. , 2019, The Journal of antimicrobial chemotherapy.

[15]  J. Brunel,et al.  Antibiotic Adjuvants: Make Antibiotics Great Again! , 2019, Journal of medicinal chemistry.

[16]  P. Yeh,et al.  Variation in Mutant Prevention Concentrations , 2019, Front. Microbiol..

[17]  M. Tyers,et al.  Drug combinations: a strategy to extend the life of antibiotics in the 21st century , 2019, Nature Reviews Microbiology.

[18]  Ana Rita Brochado,et al.  Species-specific activity of antibacterial drug combinations , 2018, Nature.

[19]  R. Stein,et al.  Increased Degree of Unsaturation in the Lipid of Antifungal Cationic Amphiphiles Facilitates Selective Fungal Cell Disruption. , 2018, ACS infectious diseases.

[20]  Michelle F. Richter,et al.  Predictive compound accumulation rules yield a broad-spectrum antibiotic , 2017, Nature.

[21]  Jonathan M Stokes,et al.  Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance , 2017, Nature Microbiology.

[22]  R. Serra,et al.  Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus , 2015, Expert review of anti-infective therapy.

[23]  K. Lewis,et al.  A new antibiotic kills pathogens without detectable resistance , 2015, Nature.

[24]  M. Webber,et al.  Molecular mechanisms of antibiotic resistance , 2014, Nature Reviews Microbiology.

[25]  E. P. Dellinger,et al.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  R. Gennis,et al.  Characterization of the type 2 NADH:menaquinone oxidoreductases from Staphylococcus aureus and the bactericidal action of phenothiazines. , 2014, Biochimica et biophysica acta.

[27]  Jesmin Akter,et al.  A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity , 2013, The Journal of Antibiotics.

[28]  E. Brown,et al.  Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. , 2013, Chemistry & biology.

[29]  Mike Tyers,et al.  Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. , 2011, Nature chemical biology.

[30]  P. Mehler,et al.  Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  S. Ōmura,et al.  Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis. , 2009, Journal of biochemistry.

[32]  Roy Kishony,et al.  Drug interactions and the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[33]  S. Ōmura,et al.  Identification of new inhibitors for alternative NADH dehydrogenase (NDH-II). , 2009, FEMS microbiology letters.

[34]  L. Rice.  Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. , 2008, The Journal of infectious diseases.

[35]  R. Kishony,et al.  Antibiotic interactions that select against resistance , 2007, Nature.

[36]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[37]  E. Padan,et al.  2‐Aminoperimidine, a specific inhibitor of bacterial NhaA Na+/H+ antiporters , 2005, FEBS letters.

[38]  F. Odds,et al.  Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.

[39]  R. Hancock,et al.  Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. , 2002, Current drug targets. Infectious disorders.

[40]  Xilin Zhao,et al.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  I. Wilson,et al.  Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. , 2000, European journal of biochemistry.

[42]  L. P. Candeias,et al.  The catalysed NADH reduction of resazurin to resorufin , 1998 .